271 related articles for article (PubMed ID: 19653866)
21. Impact of IL-1β and the IL-1R antagonist on relapse risk and survival in AML patients undergoing immunotherapy for remission maintenance.
Grauers Wiktorin H; Aydin E; Christenson K; Issdisai N; Thorén FB; Hellstrand K; Martner A
Oncoimmunology; 2021; 10(1):1944538. PubMed ID: 34367728
[TBL] [Abstract][Full Text] [Related]
22. Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinoma.
Perz JB; Ho AD
Future Oncol; 2008 Apr; 4(2):169-77. PubMed ID: 18407731
[TBL] [Abstract][Full Text] [Related]
23. Modifying the biological response to acute myeloid leukemia I. BCG, allogeneic leukemic cells and spontaneous cytotoxicity.
Arends-Merino A; Sjögren AM; Reizenstein P
Anticancer Res; 1983; 3(4):239-41. PubMed ID: 6576728
[TBL] [Abstract][Full Text] [Related]
24. Pre-eminence and persistence of immature natural killer cells in acute myeloid leukemia patients in first complete remission.
Dauguet N; Récher C; Demur C; Fournié JJ; Poupot M; Poupot R
Am J Hematol; 2011 Feb; 86(2):209-13. PubMed ID: 21264910
[TBL] [Abstract][Full Text] [Related]
25. Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia.
Wendelbo Ø; Nesthus I; Sjo M; Paulsen K; Ernst P; Bruserud Ø
Cancer Immunol Immunother; 2004 Aug; 53(8):740-7. PubMed ID: 15133630
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant histamine in cancer immunotherapy.
Hellstrand K; Hansson M; Hermodsson S
Semin Cancer Biol; 2000 Feb; 10(1):29-39. PubMed ID: 10888269
[TBL] [Abstract][Full Text] [Related]
27. Spotlight on histamine dihydrochloride in acute myeloid leukaemia.
Yang LP; Perry CM
Drugs Aging; 2011 Apr; 28(4):325-9. PubMed ID: 21428467
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
[TBL] [Abstract][Full Text] [Related]
29. Impact of NK Cell Activating Receptor Gene Variants on Receptor Expression and Outcome of Immunotherapy in Acute Myeloid Leukemia.
Hussein BA; Hallner A; Wennström L; Brune M; Martner A; Hellstrand K; Bernson E; Thorén FB
Front Immunol; 2021; 12():796072. PubMed ID: 34956230
[TBL] [Abstract][Full Text] [Related]
30. Peptide vaccines for patients with acute myeloid leukemia.
Schmitt M; Casalegno-Garduño R; Xu X; Schmitt A
Expert Rev Vaccines; 2009 Oct; 8(10):1415-25. PubMed ID: 19803762
[TBL] [Abstract][Full Text] [Related]
31. Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells.
Greiner J; Bullinger L; Guinn BA; Döhner H; Schmitt M
Clin Cancer Res; 2008 Nov; 14(22):7161-6. PubMed ID: 19010831
[TBL] [Abstract][Full Text] [Related]
32. Histamine dihydrochloride and interleukin-2 in the treatment of acute myeloid leukemia.
Stadtmauer EA
Semin Oncol; 2002 Jun; 29(3 Suppl 7):47-51. PubMed ID: 12068389
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy in the management of myelogenous leukemia.
Fairley GH
Arch Intern Med; 1976 Dec; 136(12):1406-12. PubMed ID: 793553
[TBL] [Abstract][Full Text] [Related]
34. Relapse Prevention in Acute Myeloid Leukemia: The Role of Immunotherapy with Histamine Dihydrochloride and Low-Dose Interleukin-2.
Montesinos P; Buccisano F; Cluzeau T; Vennström L; Heuser M
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791903
[TBL] [Abstract][Full Text] [Related]
35. Immune response as a possible mechanism of long-lasting disease control in spontaneous remission of MLL/AF9-positive acute myeloid leukemia.
Müller-Schmah C; Solari L; Weis R; Pfeifer D; Scheibenbogen C; Trepel M; May AM; Engelhardt R; Lübbert M
Ann Hematol; 2012 Jan; 91(1):27-32. PubMed ID: 21959947
[TBL] [Abstract][Full Text] [Related]
36. Natural killer cell immune escape in acute myeloid leukemia.
Lion E; Willemen Y; Berneman ZN; Van Tendeloo VF; Smits EL
Leukemia; 2012 Sep; 26(9):2019-26. PubMed ID: 22446501
[TBL] [Abstract][Full Text] [Related]
37. Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission.
Buyse M; Michiels S; Squifflet P; Lucchesi KJ; Hellstrand K; Brune ML; Castaigne S; Rowe JM
Haematologica; 2011 Aug; 96(8):1106-12. PubMed ID: 21546500
[TBL] [Abstract][Full Text] [Related]
38. Targeted immunotherapy in acute myeloblastic leukemia: from animals to humans.
Robin M; Schlageter MH; Chomienne C; Padua RA
Cancer Immunol Immunother; 2005 Oct; 54(10):933-43. PubMed ID: 15889256
[TBL] [Abstract][Full Text] [Related]
39. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.
Baer MR; George SL; Caligiuri MA; Sanford BL; Bothun SM; Mrózek K; Kolitz JE; Powell BL; Moore JO; Stone RM; Anastasi J; Bloomfield CD; Larson RA
J Clin Oncol; 2008 Oct; 26(30):4934-9. PubMed ID: 18591543
[TBL] [Abstract][Full Text] [Related]
40. Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia.
Martner A; Rydström A; Riise RE; Aurelius J; Anderson H; Brune M; Foà R; Hellstrand K; Thorén FB
Oncoimmunology; 2016; 5(1):e1041701. PubMed ID: 26942055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
